Description
The cyclin-
dependent kinase 2 (Cdk2) works with cyclins A or E to regulate S phase and G
2-
M transition during the cell cycle. Cdk2 Inhibitor II is a 3-
(benzylidne)indolin-
2-
one analog that selectively and potently inhibits Cdk2 (IC
50 = 60 nM). It is cell permeable, reversible, and ATP-
competitive.
Uses
CDK2 inhibitor II, is a potent, cell-permeable, ATP-competitive, and selective inhibitor of Cdk2.
in vivo
CDK2-IN-3 (2.5-250 μg, topical application, once daily, for 1 week) significantly reduces the incidence of alopecia in neonatal rat model induced by the combination of cyclophosphamide (HY-17420) and doxorubicin (HY-15142A)[1].
| Animal Model: | Cyclophosphamide (HY-17420)-Doxorubicin (HY-15142A) combination chemotherapy-induced alopecia neonatal Sprague-Dawley rat model (13 days) |
| Dosage: | 2.5-250 μg |
| Administration: | Topical application, once daily for 1 week |
| Result: | Effectively prevented alopecia in 50% of rats and provided partial protection in an additional 20%. |
References
[1] FUNK J. Cell Cycle Checkpoint Genes and Cancer[C]. 2006: 0. DOI:
10.1038/npg.els.0006046[2] STEPHEN T. DAVIS, JR. Prevention of Chemotherapy-Induced Alopecia in Rats by CDK Inhibitors[J]. Science, 2001, 291 5501. DOI:
10.1126/science.291.5501.134